Cargando…

The effect of levamisole on mortality rate among patients with severe burn injuries

BACKGROUND: Burn injuries are one of the main causes of mortality and morbidity throughout the world and burn patients have higher chances for infection due to their decreased immune resistance. Levamisole, as an immunomodulation agent, stimulates the immune response against infection. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatemi, Mohammad Javad, Salehi, Hamid, Akbari, Hossein, Alinejad, Faranak, Saberi, Mohsen, Mousavi, Seyed Jaber, Soltani, Majid, Taghavi, Shahrzad, Payandan, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872590/
https://www.ncbi.nlm.nih.gov/pubmed/24381625
_version_ 1782296984405671936
author Fatemi, Mohammad Javad
Salehi, Hamid
Akbari, Hossein
Alinejad, Faranak
Saberi, Mohsen
Mousavi, Seyed Jaber
Soltani, Majid
Taghavi, Shahrzad
Payandan, Hossein
author_facet Fatemi, Mohammad Javad
Salehi, Hamid
Akbari, Hossein
Alinejad, Faranak
Saberi, Mohsen
Mousavi, Seyed Jaber
Soltani, Majid
Taghavi, Shahrzad
Payandan, Hossein
author_sort Fatemi, Mohammad Javad
collection PubMed
description BACKGROUND: Burn injuries are one of the main causes of mortality and morbidity throughout the world and burn patients have higher chances for infection due to their decreased immune resistance. Levamisole, as an immunomodulation agent, stimulates the immune response against infection. MATERIALS AND METHODS: This randomized clinical trial was conducted in Motahari Burn Center, Tehran, Iran. Patients who had second- or third-degree burn with involvement of more than 50% of total body surface area (TBSA) were studied. The levamisole group received levamisole tablet, 100 mg per day. Meantime, both the levamisole and control groups received the standard therapy of the Burn Center, based on a standard protocol. Then, the outcome of the patients was evaluated. RESULTS: 237 patients entered the study. After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group and 85 in the treatment group. The mean age of all patients (between 13 to 64 years) was 33.29 ± 11.39 years (Mean ± SD), and it was 33.86 ± 11.45 years in the control group and 32.57 ± 11.32 years in the treatment group. The mean percentage of TBSA burn was 64.50 ± 14.34 and 68.58 ± 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA. The mortality rate was 68 (61.8%) patients in the control group and 50 (58.8%) patients in the treatment group (P = 0.8). CONCLUSION: According to this study, there was no significant relationship between improvement of mortality and levamisole consumption.
format Online
Article
Text
id pubmed-3872590
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38725902013-12-31 The effect of levamisole on mortality rate among patients with severe burn injuries Fatemi, Mohammad Javad Salehi, Hamid Akbari, Hossein Alinejad, Faranak Saberi, Mohsen Mousavi, Seyed Jaber Soltani, Majid Taghavi, Shahrzad Payandan, Hossein J Res Med Sci Original Article BACKGROUND: Burn injuries are one of the main causes of mortality and morbidity throughout the world and burn patients have higher chances for infection due to their decreased immune resistance. Levamisole, as an immunomodulation agent, stimulates the immune response against infection. MATERIALS AND METHODS: This randomized clinical trial was conducted in Motahari Burn Center, Tehran, Iran. Patients who had second- or third-degree burn with involvement of more than 50% of total body surface area (TBSA) were studied. The levamisole group received levamisole tablet, 100 mg per day. Meantime, both the levamisole and control groups received the standard therapy of the Burn Center, based on a standard protocol. Then, the outcome of the patients was evaluated. RESULTS: 237 patients entered the study. After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group and 85 in the treatment group. The mean age of all patients (between 13 to 64 years) was 33.29 ± 11.39 years (Mean ± SD), and it was 33.86 ± 11.45 years in the control group and 32.57 ± 11.32 years in the treatment group. The mean percentage of TBSA burn was 64.50 ± 14.34 and 68.58 ± 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA. The mortality rate was 68 (61.8%) patients in the control group and 50 (58.8%) patients in the treatment group (P = 0.8). CONCLUSION: According to this study, there was no significant relationship between improvement of mortality and levamisole consumption. Medknow Publications & Media Pvt Ltd 2013-09 /pmc/articles/PMC3872590/ /pubmed/24381625 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Fatemi, Mohammad Javad
Salehi, Hamid
Akbari, Hossein
Alinejad, Faranak
Saberi, Mohsen
Mousavi, Seyed Jaber
Soltani, Majid
Taghavi, Shahrzad
Payandan, Hossein
The effect of levamisole on mortality rate among patients with severe burn injuries
title The effect of levamisole on mortality rate among patients with severe burn injuries
title_full The effect of levamisole on mortality rate among patients with severe burn injuries
title_fullStr The effect of levamisole on mortality rate among patients with severe burn injuries
title_full_unstemmed The effect of levamisole on mortality rate among patients with severe burn injuries
title_short The effect of levamisole on mortality rate among patients with severe burn injuries
title_sort effect of levamisole on mortality rate among patients with severe burn injuries
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872590/
https://www.ncbi.nlm.nih.gov/pubmed/24381625
work_keys_str_mv AT fatemimohammadjavad theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT salehihamid theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT akbarihossein theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT alinejadfaranak theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT saberimohsen theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT mousaviseyedjaber theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT soltanimajid theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT taghavishahrzad theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT payandanhossein theeffectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT fatemimohammadjavad effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT salehihamid effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT akbarihossein effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT alinejadfaranak effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT saberimohsen effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT mousaviseyedjaber effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT soltanimajid effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT taghavishahrzad effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries
AT payandanhossein effectoflevamisoleonmortalityrateamongpatientswithsevereburninjuries